<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854710</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-204-407</org_study_id>
    <secondary_id>204-407</secondary_id>
    <nct_id>NCT01854710</nct_id>
  </id_info>
  <brief_title>ADASUVE 2-dose Thorough QT/QTc Study</brief_title>
  <official_title>Thorough QT/QTc Study of 2 Doses of ADASUVEÂ® in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the potential effects on the QT interval of 2 consecutive doses of ADASUVE&#xD;
      administered 2 hours apart, in relation to placebo and an active control in healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been shown in a pre-marketing clinical study that clinically relevant QT prolongation&#xD;
      does not appear to be associated with a single dose of ADASUVE. The potential risk of QTc&#xD;
      prolongation following repeat dosing is unknown. Therefore the current study will assess the&#xD;
      potential effects on the QT interval of 2 consecutive doses of ADASUVE administered 2 hours&#xD;
      apart, in relation to placebo and an active control in healthy volunteers.&#xD;
&#xD;
      The study hypothesis H0: Placebo-subtracted max mean dQTc &gt; 10 msec&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-center, randomized, double-blind, double-dummy, 2-dose, 3-period, active- and placebo-controlled, crossover QT/QTc and pharmacokinetic (PK) study of ADASUVE in healthy volunteers. All dosing and treatment-day follow-up in the study was conducted in the clinical research unit (CRU)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo</measure>
    <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
    <description>Time-matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time-matched placebo subtraction for ADASUVE treatment at 12 post-inhalation times.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTc Versus Loxapine Concentration</measure>
    <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
    <description>QTc @ Cmax based on linear and nonlinear regression of QTcI versus time matched serum loxapine concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With QTcI &gt; 450 ms</measure>
    <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
    <description>Numbers of Subjects with QTcI &gt; 450 ms at any time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With QTcI &gt; 480 ms</measure>
    <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
    <description>Numbers of Subjects with QTcI &gt; 480 ms (or 500 ms) at any time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With QTcI Increase &gt; 30 ms From Baseline</measure>
    <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
    <description>Numbers of Subjects with QTcI Increase &gt; 30 ms from Baseline at any time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With QTcI Increase &gt; 60 ms From Baseline</measure>
    <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
    <description>Numbers of Subjects with QTcI Increase &gt; 60 ms From Baseline at any time point</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)</measure>
    <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
    <description>A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADASUVE 10 mg 2 doses 2 hours apart</intervention_name>
    <description>Inhaled loxapine 10 mg 2 doses 2 hours apart</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
    <other_name>Staccato Loxapine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Placebo</intervention_name>
    <description>Staccato placebo via inhalation x 2 at 2 hours apart</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral moxifloxacin 400 mg</intervention_name>
    <description>Oral moxifloxacin 400 mg single dose</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
    <other_name>AVELOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo</intervention_name>
    <description>Oral capsule identical in appearance to moxifloxacin</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects between the ages of 18 to 65 years, inclusive.&#xD;
&#xD;
          -  Body mass index (BMI) â¥18 and â¤32.&#xD;
&#xD;
          -  Subjects who are willing and able to comply with the study schedule and requirements,&#xD;
             and stay at the CRU for a 4-day period and 2 consecutive 3-day periods.&#xD;
&#xD;
          -  Subjects who speak, read, and understand English and/or Dutch and are willing and able&#xD;
             to provide written informed consent on an IEC approved form prior to the initiation of&#xD;
             any study procedures.&#xD;
&#xD;
          -  Subjects who are in good general health prior to study participation&#xD;
&#xD;
          -  Female or male participants who agree to use a medically acceptable and effective&#xD;
             birth control method&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who regularly consume large amounts of xanthine-containing substances (â¥ 5&#xD;
             cups of coffee/day).&#xD;
&#xD;
          -  Subjects who have taken prescription or nonprescription medication within 5 days of&#xD;
             Visit 2.&#xD;
&#xD;
          -  Subjects who have had an acute illness within the last 5 days of Visit 2.&#xD;
&#xD;
          -  Subjects who have smoked tobacco within the last 30 days or who have a positive&#xD;
             cotinine test.&#xD;
&#xD;
          -  Subjects who have a history of HIV, anti-HCV or HbsAg positivity.&#xD;
&#xD;
          -  Subjects who have a history within the past 2 years of drug or alcohol dependence or&#xD;
             abuse as defined by DSM-IV.&#xD;
&#xD;
          -  Subjects who test positive for alcohol or have a positive urine drug screen.&#xD;
&#xD;
          -  Subjects who have a history of allergy or intolerance to loxapine or amoxapine or&#xD;
             history of bronchospasm following inhaled loxapine treatment.&#xD;
&#xD;
          -  Subjects who have an ECG abnormality.&#xD;
&#xD;
          -  Subjects who have hypotension, or hypertension.&#xD;
&#xD;
          -  Subjects who have a history of unstable angina, syncope, coronary artery disease,&#xD;
             myocardial infarction, congestive heart failure, transient ischemic attack, history of&#xD;
             convulsions or other neurological disorder.&#xD;
&#xD;
          -  Subjects who have a current history of asthma, chronic obstructive lung disease, or&#xD;
             any other lung disease associated with bronchospasm.&#xD;
&#xD;
          -  Subjects who use medications to treat airways disease, such as asthma or COPD.&#xD;
&#xD;
          -  Subjects who have any acute respiratory signs/symptoms (e.g., wheezing).&#xD;
&#xD;
          -  Female subjects who have a positive pregnancy test at screening or at admission to any&#xD;
             of the treatment visits, or are breastfeeding.&#xD;
&#xD;
          -  Subjects who have received an investigational drug within 60 days prior to the&#xD;
             Screening Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa Nunes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Zuidlaren</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Cassella JV, Spyker DA, Yeung PP. A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. Int J Clin Pharmacol Ther. 2015 Nov;53(11):963-71.</citation>
    <PMID>26501204</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <results_first_submitted>March 13, 2017</results_first_submitted>
  <results_first_submitted_qc>September 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2017</results_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADASUVE</keyword>
  <keyword>inhaled loxapine</keyword>
  <keyword>thorough QT/QTc study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence ABC</title>
          <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence ACB</title>
          <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence BCA</title>
          <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence BAC</title>
          <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
        </group>
        <group group_id="P5">
          <title>Treatment Sequence CAB</title>
          <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
        </group>
        <group group_id="P6">
          <title>Treatment Sequence CBA</title>
          <description>Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>CRI procedural error</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population (N=60)</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects Treated</title>
          <description>All 6 treatment sequences = Safety Population</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="14.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo</title>
        <description>Time-matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time-matched placebo subtraction for ADASUVE treatment at 12 post-inhalation times.</description>
        <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
        <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between Adasuve and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>ADASUVE-Placebo Crossover Subjects</title>
            <description>All subjects who completed both treatments A and B: Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo.&#xD;
The analyses are based on a within (paired) comparison of the time matched drug - placebo QTc values.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo</title>
          <description>Time-matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time-matched placebo subtraction for ADASUVE treatment at 12 post-inhalation times.</description>
          <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between Adasuve and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" lower_limit="1.77" upper_limit="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTc Versus Loxapine Concentration</title>
        <description>QTc @ Cmax based on linear and nonlinear regression of QTcI versus time matched serum loxapine concentrations</description>
        <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
        <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between Adasuve and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>ADASUVE 10 mg x 2 Doses</title>
            <description>ADASUVE QTcI, Differences from Placebo in Change from Pre-dose Baseline and One-sided 95% Upper Confidence Bound (msec)&#xD;
QTcI associated with mean Cmax</description>
          </group>
        </group_list>
        <measure>
          <title>QTc Versus Loxapine Concentration</title>
          <description>QTc @ Cmax based on linear and nonlinear regression of QTcI versus time matched serum loxapine concentrations</description>
          <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between Adasuve and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.2" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With QTcI &gt; 450 ms</title>
        <description>Numbers of Subjects with QTcI &gt; 450 ms at any time point</description>
        <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
        <population>QT population -- Comparisons were based on corrected differences between Adasuve and placebo (excluding moxifloxacin) exposure per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo + Oral Placebo</title>
            <description>Staccato Placebo 2 doses 2 hours apart + Oral Placebo&#xD;
Staccato Placebo 2 doses 2 hours apart: Inhaler with no drug in it to mimic the ADASUVE inhaler&#xD;
Placebo (for moxifloxacin): placebo capsule to mimic moxifloxacin 400 mg</description>
          </group>
          <group group_id="O2">
            <title>ADASUVE 10 mg x 2 Doses</title>
            <description>ADASUVE 10 mg 2 doses 2 hours apart + Oral Placebo&#xD;
ADASUVE 10 mg 2 doses 2 hours apart: inhaled loxapine&#xD;
Placebo (for moxifloxacin): placebo capsule to mimic moxifloxacin 400 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With QTcI &gt; 450 ms</title>
          <description>Numbers of Subjects with QTcI &gt; 450 ms at any time point</description>
          <population>QT population -- Comparisons were based on corrected differences between Adasuve and placebo (excluding moxifloxacin) exposure per ICH Guideline E14 for a thorough QT study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With QTcI &gt; 480 ms</title>
        <description>Numbers of Subjects with QTcI &gt; 480 ms (or 500 ms) at any time point</description>
        <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
        <population>QT population -- Comparisons were based on corrected differences between Adasuve and placebo (excluding moxifloxacin) exposure per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo + Oral Placebo</title>
            <description>Staccato Placebo 2 doses 2 hours apart + Oral Placebo&#xD;
Staccato Placebo 2 doses 2 hours apart: Inhaler with no drug in it to mimic the ADASUVE inhaler&#xD;
Placebo (for moxifloxacin): placebo capsule to mimic moxifloxacin 400 mg</description>
          </group>
          <group group_id="O2">
            <title>ADASUVE 10 mg x 2 Doses</title>
            <description>ADASUVE 10 mg 2 doses 2 hours apart + Oral Placebo&#xD;
ADASUVE 10 mg 2 doses 2 hours apart: inhaled loxapine&#xD;
Placebo (for moxifloxacin): placebo capsule to mimic moxifloxacin 400 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With QTcI &gt; 480 ms</title>
          <description>Numbers of Subjects with QTcI &gt; 480 ms (or 500 ms) at any time point</description>
          <population>QT population -- Comparisons were based on corrected differences between Adasuve and placebo (excluding moxifloxacin) exposure per ICH Guideline E14 for a thorough QT study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With QTcI Increase &gt; 30 ms From Baseline</title>
        <description>Numbers of Subjects with QTcI Increase &gt; 30 ms from Baseline at any time point</description>
        <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
        <population>QT population -- Comparisons were based on corrected differences between Adasuve and placebo (excluding moxifloxacin) exposure per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo + Oral Placebo</title>
            <description>Staccato Placebo 2 doses 2 hours apart + Oral Placebo&#xD;
Staccato Placebo 2 doses 2 hours apart: Inhaler with no drug in it to mimic the ADASUVE inhaler&#xD;
Placebo (for moxifloxacin): placebo capsule to mimic moxifloxacin 400 mg</description>
          </group>
          <group group_id="O2">
            <title>ADASUVE 10 mg x 2 Doses</title>
            <description>ADASUVE 10 mg 2 doses 2 hours apart + Oral Placebo&#xD;
ADASUVE 10 mg 2 doses 2 hours apart: inhaled loxapine&#xD;
Placebo (for moxifloxacin): placebo capsule to mimic moxifloxacin 400 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With QTcI Increase &gt; 30 ms From Baseline</title>
          <description>Numbers of Subjects with QTcI Increase &gt; 30 ms from Baseline at any time point</description>
          <population>QT population -- Comparisons were based on corrected differences between Adasuve and placebo (excluding moxifloxacin) exposure per ICH Guideline E14 for a thorough QT study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With QTcI Increase &gt; 60 ms From Baseline</title>
        <description>Numbers of Subjects with QTcI Increase &gt; 60 ms From Baseline at any time point</description>
        <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
        <population>QT population -- Comparisons were based on corrected differences between Adasuve and placebo (excluding moxifloxacin) exposure per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo + Oral Placebo</title>
            <description>Staccato Placebo 2 doses 2 hours apart + Oral Placebo&#xD;
Staccato Placebo 2 doses 2 hours apart: Inhaler with no drug in it to mimic the ADASUVE inhaler&#xD;
Placebo (for moxifloxacin): placebo capsule to mimic moxifloxacin 400 mg</description>
          </group>
          <group group_id="O2">
            <title>ADASUVE 10 mg x 2 Doses</title>
            <description>ADASUVE 10 mg 2 doses 2 hours apart + Oral Placebo&#xD;
ADASUVE 10 mg 2 doses 2 hours apart: inhaled loxapine&#xD;
Placebo (for moxifloxacin): placebo capsule to mimic moxifloxacin 400 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With QTcI Increase &gt; 60 ms From Baseline</title>
          <description>Numbers of Subjects with QTcI Increase &gt; 60 ms From Baseline at any time point</description>
          <population>QT population -- Comparisons were based on corrected differences between Adasuve and placebo (excluding moxifloxacin) exposure per ICH Guideline E14 for a thorough QT study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)</title>
        <description>A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec</description>
        <time_frame>Predose, 2 min, 1, 1.5 hr, 2 hr 2 min, 2 hr 5 min, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
        <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between moxifloxacin and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin QT Crossover Subjects</title>
            <description>All subjects who completed both Treatments B and C: B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo.&#xD;
Analyses are based on a within (paired) comparison of the time matched drug - placebo QTc values.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)</title>
          <description>A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec</description>
          <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between moxifloxacin and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.47" lower_limit="8.13" upper_limit="12.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first exposure to study treatment to 30 days after last exposure to study treatment</time_frame>
      <desc>Adverse events (AEs) were assessed pre-dose and at 12 prespecified time points</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Placebo + Oral Placebo</title>
          <description>Staccato Placebo 2 doses 2 hours apart + Oral Placebo&#xD;
Staccato Placebo 2 doses 2 hours apart: Inhaler with no drug in it to mimic the ADASUVE inhaler&#xD;
Placebo (for moxifloxacin): placebo capsule to mimic moxifloxacin 400 mg</description>
        </group>
        <group group_id="E2">
          <title>ADASUVE 10 mg x 2 Doses</title>
          <description>ADASUVE 10 mg 2 doses 2 hours apart + Oral Placebo&#xD;
ADASUVE 10 mg 2 doses 2 hours apart: inhaled loxapine&#xD;
Placebo (for moxifloxacin): placebo capsule to mimic moxifloxacin 400 mg</description>
        </group>
        <group group_id="E3">
          <title>Oral Moxifloxacin</title>
          <description>Staccato Placebo 2 doses 2 hours apart + Oral moxifloxacin 400 mg&#xD;
Oral moxifloxacin 400 mg&#xD;
Staccato Placebo 2 doses 2 hours apart: Inhaler with no drug in it to mimic the ADASUVE inhaler</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The use of healthy subjects, which precludes observation of drug-induced QTc prolongation in a population with additional factors predisposing to TdP. Subjects with respiratory disease were excluded.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7777</phone>
      <email>jcassella@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

